Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors (NCT02644291) (2022)

Government Record · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (sponsor) · June 23, 2022

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (sponsor), 2022-06-23: Registry record for a completed Johns Hopkins phase 1 trial of oral mebendazole in children and young adults with recurrent or progressive brain tumors. It lists 16 actual enrollees and no posted results.

we have shown efficacy in preclinical laboratory models of high grade glioma and medulloblastoma

n/a

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (sponsor), 2022-06-23: Registry record for a completed Johns Hopkins phase 1 trial of oral mebendazole in children and young adults with recurrent or progressive brain tumors. It lists 16 actual enrollees and no posted results. Record field quoted from the brief summary; registry record. Study type: phase 1, 3+3 dose escalation. N=16 actual. Country: United States. Dose: three dose levels of oral mebendazole three times daily, chewable 500 mg tablets, continued until toxicity or progression (the published report used 1250, 1875 and 2500 mg/m2/day). Sponsor: Johns Hopkins. Status: COMPLETED; start 2016-05; completion 2022-06-09. hasResults=false. Comparator: none. Results published by Phan et al. 2025 (MBC-14). Registry entry; no results posted.